The introduction ofnewer surgica l and combined-modality approaches to organ pres ervation in pat ient s with advanced laryngeal or liyp oph aryngea! ca nce r is the most exc iting clinical frontier in head and neck can cer treat ment today. The use ofthese techniques at other sites, the exp loration ofimproved methodsfor patient selection and tumor assessment , and the 'development oj nelVer combination regimens will need to be rigorou sly st udied infuture clinica l trials. ln all these efforts, the majorfocus mu st remain on imp roving survival. This article re view s the latest dev elopments in organ-p rese rvat ion strategies and techniques fo r patients with advanced la ryn geal or liyp opharyngeal cance r.
Introduction
T he goa l of preserving laryn geal function and struc ture has do minate d efforts to develop newer trea tme nt approaches to patie nts with adva nced (stage III or IV) ca nce r of the laryn x or hypoph arynx. Tr adit ional trea tme nt has co nsisted of total laryngectomy , usually combined with neck dissect ion and adj uva nt pos topera tive radiat ion therapy. In most cases of ad vance d disease, total laryngectomy has resulted in 2-year cure rates in the range of 60 to 70 % for laryngeal ca ncer and 40 to 50 % for hypopharyngea l cancer.
Th e introduc tion of neoadj uva nt chemotherapy into multidi sc iplinary management during the late 1970s led to observations that high rate s of complete respo nse ca n be ac hieved and that some pat ient s who respond to chemot herapy might be cured with subsequent radiation alone. T hese findi ngs led inve stigators to conduct two large, ca refully performed, randomized , prospective stud-ies of patient s with laryngeal I and hypoph aryngeaf ca ncer. Th ese studies showed that survival rates were not co mpromised when treatment regi me ns that incl uded two or three cycles of neoadj uva nt cisplatin/5-f1uoro uraci l (5-FU) were used to select patients for defi nitive radi ation therapy. Altho ug h planned laryn gectomy for nonresponders was an integral part of these treatment regimens, 40 to 65 % of patients were able to-avoid sa lvage laryngectom y. These findi ngs opened new frontiers in the development of trea tment options for patients with head and neck cancer. In developing these new organ-preservation approaches, researcher s have placed additio na l emp hasis on quality-of-life issues rather than concentrating exc lusive ly on improvemen ts in survival.
Surgeons who care for pat ien ts wi th laryngeal or hypopharyngeal ca ncer have pioneered tiss ue-conse rvatio n and -recon stru ction techn iques that maximize the funct ion of laryngeal remn ant s follow ing partial laryngea l resec tio ns. The horizon s of such surgical organprese rvation techn iques were recentl y expanded by the intro duction and popul arization of supracricoid partial laryngectom y. This relati vely new technique, whic h was developed in Eur ope, has yie lded excellen t cure rates for advanced T2 and so me T3 cancers. " Supracricoid par tial laryngectomy obvia tes the need for permanent tracheostomy , does no t res ult in significant swallowing dysfunction, and preserves reasonable voice quali ty. Selection criteria for such preci se resections, however, are comple x, and the extent of tumor mu st be carefully defined.
T his article outli nes fund amental treatment considerations co mmon to all pati en ts, var iou s alternatives for organ pre servation, and principles established thus far for treatment strategies that com bine che mo therapy and radiation for organ pre servatio n.
Structure vs function
It is impo rtan t to differentiate between orga n-preservation op tio ns that relate to mai ntenance of structure and those that pert ain to maintenance of j unction. For example, many treatments, both surg ica l and nonsur gical, ca n preserve the struc ture of the larynx but significa ntly comprom ise its function. Cri tica l analyses of new treatment approaches that combine chemotherapy and radiation must recognize that the maintenance of the airway (no tracheostom y), swallowing funct ion (no asp irat ion or feed ing tube), and speech are the critica l laryngeal functions that have an imp act on quality of life. A treatm ent that does not preserve these functions ca nnot be co nsi dered to be a successful orga n-preservation techn ique, eve n if the orga n re mai ns in situ.
Patients generally value airway and swallowing functions more than they do speech ability.' Ill-conceived notions of organ preservation (bot h surgical and nons urgical) that res ult in preservation of nonfunctional laryngea l struct ures in an attem pt to preserve vo ice sho uld be discouraged . Tracheoesoph ageal punct ure tech niques have greatly improved voice res toration ra tes follow ing total laryngectomy, and mos t patients are able to speak in a hoarse but natural-sound ing voice. Th erefore, voice preservation is the least important quality-of-life co nsideration in the dec isio n-making process.
Standard treatment considerations
In disc uss ing what is experime ntal and what is "standard of care," it is useful to rev iew some acce pted ge neral treatment recommendations and to co nsider what we have learned fro m our exte nsive ex perience wit h chemo therapy and radia tio n for organ preservation:
• All patients sho uld undergo a mu ltid iscip linary evalua tio n-inc ludi ng endoscopy, ade quate biopsy, and ra diologic imaging-to fully determine the extent of the tumor. • Treatment alternatives, success rates , expected morbid ity, potential complications, and followup req uirements must be ca refully explai ned to all patie nts. • Meth ods of maintainin g speech, swallowi ng, and resp iration mus t be fully ex plained to eac h patient. • A head and neck surg ica l oncologist should supervise tum or staging and fo llow-up exa mination s. • Combined chemothera py and radiat ion for orga n preservation is ind icated only for patients who are fac ing total laryngectom y.
Th e proli feration of co mbined chemotherapy and radia tion protocols for head and neck ca ncer has given rise to a maj or trea tme nt concern. Th is concern is that patients who are eligible for a co nventional, nonmorb id, singlemoda lity, organ-preserving, cura tive trea tme nt (e.g., co nservation lar yngectomy or radiation alone) might instead be treat ed with an intensive, tox ic combi nat ion regimen that has not been proven to be supe rior in random ize d 898 comparisons . Moreover, surv iva l can be jeopardized by poor management, inadequate fo llow -up, or de layed detec tion of rec urrence. All too often, patie nts with persistent or rec urren t laryngeal or hypoph aryngeal ca ncer are referred to surgeons in ter tiary care cen ters following combine d chemotherapy and radiation in the hope that some curative sa lvage resection can be performed . In such sit uations, the or igi na l extent of the tum or is largely unknow n, the potentia l adequacy of salvage resection cannot be assured, life-threaten ing surg ica l complicatio ns are common, and recu rrent tumors are often unresectable by the time they are clinica lly detected. Th erefore, it is crit ica lly important that ex perimental treatment be different iated fro m co nve ntio nal treatment so that patie nts ca n make infor med decisions an d understand the risks of uncon ventional trea tment, as well as the importance of d iligent tum or surveilla nce .
Organ-preservation options
Patients who face possible total laryngectom y for laryngea l or hypopharyngeal ca ncer have three options for organ-preservation treatment: orga n-preserving surgery, definitive radia tio n therapy, and neoadjuvant chemotherapy and rad iation . A four th protocol that is bei ng studied, with mixed res ults, is conc urrent chemoradiation.
Organ-preserving surge ry. One surgical option is subtotal laryngectomy and/or partial phary ngec tomy, whic h offers several advantages : a precise de linea tio n of the tumor, acc urate margin assessment, optima l neck management, and the maintena nce of ade quate airway and swallow ing func tions (altho ugh the res ultant vo ice quality is usuall y poor). Th is type of surgery requires careful patient selectio n and tec hnica l expertise . Th ese procedures are partic ula rly usefu l in patients who have tra nsg lottic cancers and selected glottic or supraglottic cance rs that fea ture limited voca l fold mobility. Postoperative speech and swallowing rehabilita tion is necessary for these patients. Local co ntro l rates range from 93 to 100%,304
Another alternative to total laryngectomy is the neartotal laryngectomy described by Pearson et a1. 6 Th e technique is simi lar to a total laryngectomy on the moreinvolved side and a supraglott ic laryngectomy on the lessinvo lved side . Th e surgeon uses a narrow myomu cosal strip of larynx to co nnec t the trac hea and the phary nx while preserving one functiona l aryteno id. This crea tes a dynamic shunt tha t prevents aspiration an d allows speech wit hou t the need for a pros thes is, although the patient remai ns dependent on a trac heostoma fo r respiratio n.
Definitive radiation th erapy. In general, the res ults of radiation alone fo r advanced hypophary ngeal ca ncer are poor,"? as are the res ults for pat ients wit h laryngeal cancer who have clinically invo lved neck metastases.'?'!' Some patien ts who have small primary tum ors th at are amenable to co nservation surgery are occasionally treated wit h radia tion to the primary site in combinatio n with neck dissection.'? Altho ugh radiation obviates the need for primary surgical resection, many patients eventually lose their larynx as a resu lt of local recu rrence.
A direct co mparison of radiation alone to surgery has not been reported. All definiti ve radiation approaches rely on successful surg ical salvage oflocal or regio nal failures in order to ach ieve survival rates that approach those of primary surgery. Thus, the invo lvemen t of the surgeo n in staging and surve illance is cri tica l. The long-term toxicity of high-dose radiation is ofte n underappreciated, but it is clear that chro nic fibrosis, edema, tissue necrosis, and dysphagia are not uncomm on and that their incide nce increases with more aggress ive acce lerated fractionation sche mes and with long-t erm (>5 yr) follow -up.
Neoadj uvant chemotherapy and radiation. Most investiga tors have now accep ted neoadju vant che mothera py co mbi ned with radiation and surgical salvage as a standar d alterna tive to immed iate laryngectom y." Thi s accep tance is base d on the results of two published randomized trials: the Departm ent of Veterans Affairs Laryngeal Cancer Study! and the European Organization for Researc h and Treatment of Cancer (EO RTC) phase III trial. 2 Th ese two studies showed that patients with adva nced laryngeal or hypopharyngeal cancer who were treated wit h combined che mo radia tion and surgical salvage experienced surviva l rates simi lar to those who were trea ted with conventional total laryngectomy. Although neoadj uva nt che motherapy combined wit h radiatio n has bee n em brace d by many as a good alterna tive to immediate laryngectomy, the rate of salvage laryngectom y varies from 30 to 50 %; to some, this is unaccept ably high . If appro priate and timely surg ical salvage cannot be performed, the possible resultant decrease in surviv al ca nnot be ju stifi ed .
Surv iva l rates in the VA study illustrate the potent ial problem s that are face d if salvage surge ry is not an integral part of treatment. I Differences in survi val in favo r of surgery were 0% at2 years , 3% at 3 years, 8% at4 years, and 5% afte r I0 years ." None of these differences is statistically significant. T his is part ly beca use the survival rate in the chemotherapy gro up wit h orga n preservation was nearly identical to the surv iva l rate of the surgical salvage grou p. Duplication of these organ-preservation and survival rates at sites outside the larynx mig ht be more difficult to achieve in cases where barriers to submucosal tumor spread are less we ll developed and radical surgery is less stan dar dized.
Concurrent chemoradiation, Emerging data from
several randomized trials sugges t that che mothera py admi nistere d during radia tio n might improve local co ntro l rates (and in some instances eve n surviva l rates) to a greater degree than does radiation alone.":" The result s of a large, well-do ne meta-analysis by Pignon et aI, who looked at the effects of chemotherapy added to Volume 80, Number 12 locoregional treatment , suggested that a significant surviva l ben efit (8%) was associated with concomitant chemoradiation sched ules. IS Trials with direct comparisons to surgery, however, have not been performed.
The best drugs, schedules, and dosages have not yet been determined for concurrent chemotherapy and radiation . The most widely used regi men incorporates cisp latin wit h standa rd fractionatio n radiation on days 1, 22, and 43 of the rad iation schedule. Concern s abo ut concurren t chemotherapy and radiatio n protocols relate to higher toxic ity, a treatm ent-related mortality rate of 2 to 3%, more severe late toxicity, higher co mplica tion rates for salvage surge ry, and the risk that radia tion treatm ent might need to be interrupted or the dose might need to be reduced because of the development of mucositis. A numb er of intensive, multidisciplinary chemoradiation schedu les are curren tly under inves tiga tion.
Investigators conducting a rece ntly co mpleted rando mized intergroup trial (R9 1-11) co mpared the effectiveness of the neoadju vant approac h (in whic h chemotherapy is used to selec t patie nts for radiation, simi lar to the VA trial) to the effec tive ness of defi nitive radiation alone and of co mbine d co ncurrent chemo radiation for patients wit h T3 and selec ted T4 laryngeal cancers. One wo uld anticipate that pa tie nts who unde rwe nt co nc urrent chemoradia tion would do better than those who received radiation only. However, according to a recentl y published report of preli minary results , the re was no difference in 2-year surviva l rates among the three treatment arms." These early findings are disappointing because they do not fulfill the promi se of the obse rvations made by Pignon et al. IS Th e R91-11 trial data do sugges t that the appearan ce of distant metastases seemed to be delayed in both of the chem otherap y arms. Moreover, sig nifica ntly higher rates of laryngeal preservation at 2 years were seen in the co ncurrent che moradiation arm (88 %) tha n in the induction arm (74%) and the standard radiation ar m (59%). Toxicit y in both of the chemotherapy arms was significantly greater than that in the radiation-alone arm, and more of these patients required dose red uctions or underwent incomplete definitive radi ation courses . A serious concern with the induction arm was the fail ure to perfo rm planned laryngectomy followi ng a poor response to induction chemotherapy in a large number of patients who we re randomized to that group. The trea tment strategy for the induction arm differed significantly from that of the other two arms in that the response to chemotherapy was used to select patients for radiation. In the other two arms , all patie nts received definitive radiation; surgery was not a planned part of treatm ent. It will be important to carefully analyze salvage lary ngec tomy rates, co mplications, quality of life, and long-term surviva l amo ng the three gro ups in this study before any conclusio ns ca n be drawn rega rding the best standard of therap y.
W OLF
Anoth er inno vative approach that has recentl y been reported uses a rapid tumor respon se to a single cycle of induction chemotherapy to select tho se patient s who will undergo concurrent chem otherapy and defin itive radi ation, as was the case in the R91 -l l trial.20,21 Follow ing radi ation therapy, two cycles of additional adj uva nt cispla tin/S-FU are admin istered in an attempt to address dissemi nated disease. Using this approach, inves tigators have reported dramatically improved survival rates and decreased late salvage laryngec tomy rates co mpare d wit h those seen follow ing previous organ-prese rva tion regimens.
Many questions still exist regarding organ-prese rvation treatm ent approaches that incorporate chemotherap y and radiation. On ly the neo adjuvant approach has been prospectively studied in randomized trials. It is unclear whet her only those who respond to chemotherapy are goo d candidates and whether the degree or spee d of response to chemot herapy is imp ortant. The number of cycles of chemotherapy necessary to achieve success is unclear. The best meth od of monitoring response and performing tum or surve illance is also uncl ear. Preliminary data fro m some centers sugges t that ser ial positronemi ssion tomograph y and identification of biologic markers might be usefu l in selecting patient s and for tumor surve illance . Unt il the answers to such questions are know n, there are littl e data avai lable to define a standard approach. Thi s paucity of data, by necessity, relegates chemoradiation paradigms to an investigational role.
Lessons learned
Despite a lack of definitive data, a numb er of general prin ciples have emerged from the accumulated experience of num erous investigators. Th ese lessons learned from chemoradiation organ-preserva tion trials should form the basis for curre nt treatm ent practice until newer data emerge fro m future clinical trials:
Comparison ofoutco mes. There have been no randomized trials co nducted in which inves tigators have co mpared surgery alone to radiation therapy alone for advanced laryngeal or hypopharyngeal cancer. Thu s, compara tive outco mes in terms of quality oflife, function, and surviva l are unknown except in the setting of neoa dj uva nt chemotherapy and radiat ion. Availabl e data are based on the mature, randomi zed VA and EORTC studies. 1, 2 Neck management. In patients with advanced locoregional disease, management of the neck is the single most important facto r in survival. Therefore, neck manage ment strategies must be co mpre hensive, and they might differ from those emp loyed in the management of the primary site. For patien ts wit h large cli nica l metastases, plan ned neck dissec tions before or after radiation should be considered.s-" Pretreatment imaging. Surgic al salvage is an integral part of chemoradiation protoco ls for orga n preservation . 900 Prop er staging and pretreatment assessme nt of tumor extent, planning for potential surgical resection, and tattooing of potent ial resec tion margins are critical. Many patients will benefit from pretreatm ent ev aluation by computed tom ograph y or magneti c resonance imagin g, particul arly to delineate the extent of the tumor in preepiglottic and paraglotti c spaces. For some patient s who have deeply invasive or submucosal tumors, these radiologic images are the best means of measuring tumor response because surface meas urements in such situations are often unreliabl e.
Follow -up. Clin ical surve illance of tumor recurrence and response to thera py is also critica l. Th e success of surveillance is heavily dependent on the skill and exp erience of the surgeon, and this responsibility cannot be delegated to medi cal or radia tion onco logis ts or to radiologis ts alone. Import ant observations derived from early studies include the finding that fixed vocal folds ofte n remai n fixed , eve n after tumor era dication. Th e reason is that areas of gross tumor are replaced by scarred and fibrot ic tissue. Th erefore, the larger the tumor , the less likely it is that norm al phonation will be res tored.
Aspiratio n follo wing majortumor regression is uncommon . Thi s might be attri butable to the slow disappe arance of tissue bulk durin g tumor regression , which allows patients' protecti ve swa llow ing mech ani sm s to adapt to the slow changes in laryngeal anatomy . In the VA trial, no patient required permanent tracheostom y because of aspiratio n, and only fou r of 166 (2.4 %) required per manen t tracheostomy beca use ofchronic laryngeal fibrosis, edema, or chondritis.1 Three other patients who underwent permanent tracheostom y were never rendered disease-free, and all died of cance r within 6 months of diagnosis (unpublished data, 1991).
Complications. Sur gery can be safely performed after chemotherapy witho ut a high risk of co mplications. On the other hand , the high complication rates follow ing radiatio n are well known, and eve n higher rates have been reported followi ng che moradiation.24-26 T hus, the identification of poten tial failures prior to inte nsive radiation wou ld be beneficial and would avoid unnecessary and redundant therapies.
Patient selection. Concurrent chemora dia tion regim ens might be superior to radiati on alone and super ior to ind uction chemotherapy follow ed by radi ation , particularly since induction che mothera py has failed to provide a surviva l adva ntage . Selection of the most appropriate patients for regimens that carry high toxicity and whose long-term success rates are unknown req uires careful patient counseling.
M etastases. Distant metastases remain a major cause of dea th in patients with advanced laryngeal or hypopharyngea l cancer.P :" Newer trea tments that incorpora te systemic therapy will be needed to imp rove overall survival rates. 
